In October 2021, the thymus tissue product Rethymic was approved by U.S. Food and Drug Administration (FDA) as a medical therapy for the treatment of children with<unk> . It takes six months or longer to reconstitute the immune function in treated children.
Congenital athymia
Euthymia 
Dysthymia
Cyclothymia
Minor depressive disorder
Myokymia
Atypical depression
Disruptive mood dysregulation disorder